BRCA1 and breast cancer: Although their study helped demonstrate the activity of cisplatin in BRCA1-related early BC, the patient population had extremely favourable characteristics, with 65% of women having node-negative disease and 46% having tumours ≤2 cm.85 Furthermore, it was a single-arm study and did not compare neoadjuvant cisplatin to standard anthracycline-based chemotherapy; that question is being addressed by the ongoing randomised neoadjuvant INFORM/TBCRC 031 study (NCT01670500).